FDA sounds the alarm on Pfiz­er’s block­buster Xel­janz af­ter a high dose was linked to a high­er death rate, blood clots

The FDA is sound­ing a for­mal warn­ing about the po­ten­tial safe­ty haz­ard posed by a high dose of Pfiz­er’s block­buster Xel­janz, tak­ing a move that could put a se­ri­ous crimp in its block­buster sales rev­enue.

Their state­ment to­day in­cludes:

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.